Sorted CM and EM T cells from treated humanized tumors showed that TUSC2 addition to carboplatin and pembrolizumab correlated with a significant increase of (a) IFN-γ levels, after tumor antigens exposure, indicating antigen-specific immune responses of the tested memory T cells; and (b) tissue-resident T-memory cells (TRM). Here, IFNG is linked to neoplasm.